Automation enables intensification of downstream processes.
Automation and digitalization work together in the digital plant.
Precompetitive consortiums seek solutions to industry-wide challenges.
BioPharm International spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors.
Flexible and efficient methods are needed for biopharmaceutical manufacturing.
The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.
Innovations aid efficient processing.
Isolators move into smaller-volume processes, including cell and gene therapy manufacturing.
Disposable equipment components find use in small-volume aseptic biopharmaceutical manufacturing.
A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.